

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strikethrough~~ and additions are underlined.

## Listing of Claims:

1. (Original) A cancer gene therapeutic drug comprising a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to administration of a carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration so as to make the oncolytic virus act on a tumor cell within the living body.
2. (Currently amended) The cancer gene therapeutic drug according to claim 1, wherein the virus for immunological treatment and the oncolytic virus are selected from the group consisting of adenovirus, herpes virus, lentivirus, ~~such as~~ HIV virus, retrovirus, reovirus, vesicular stomatitis virus (VSV) and any other oncolytic viruses.
3. (Currently amended) The cancer gene therapeutic drug according to claim 1-~~or~~-2, wherein the virus for immunological treatment is a non-proliferative type and/or an inactivated virus.
4. (Currently amended) The cancer gene therapeutic drug according to ~~any one of~~ claims 1 to-3, wherein the carrier cell is selected from the group consisting of A549 cell, 293 cell, SW626 cell, HT-3 cell, PA-1 cell, ~~and any other~~ a human derived cancer cell, and a human or normal cell.
5. (Currently amended) The cancer gene therapeutic drug according to claim 1, wherein the oncolytic virus to be infected to the carrier cell has a promoter selected from the group consisting of 1A1.3B promoter, midkine promoter, β-HCG promoter, SCCA1 promoter, cox-2 promoter,

PSA promoter ~~or another~~ and a tumor specific promoter, according to a kind of cancer to be treated etc.

6. (Original) The cancer gene therapeutic drug according to claim 1, further comprising atelocollagen.

7. (Original) The cancer gene therapeutic drug according to claim 1, further comprising a GM-CSF expression vector to be infected to the carrier cell before administration.

8. (Original) The cancer gene therapeutic drug according to claim 1, further comprising an iron preparation and/or a porphyrin compound.

9. (Original) The cancer gene therapeutic drug according to claim 1, further comprising a tumor cell to be administered for tumor vaccination.

10. (Original) A cancer gene therapeutic method comprising a step for administration of a virus for immunological treatment to induce a CTL reaction within a human body to administration of a carrier cell; and after a predetermined period, a step for at least one administration of a carrier cell to be infected with an oncolytic virus before the administration so as to make the oncolytic virus act on a tumor cell within the human body.

11. (Currently amended) The cancer gene therapeutic method according to claim 10, wherein the period from administration of the virus for immunological treatment to administration of the carrier cell is set at about two weeks ~~or more, and to~~ not more than 13 weeks.

12. (Original) The cancer gene therapeutic method according to claim 10, wherein the administration rate of the virus for immunological treatment is set between about  $10^5$  viral particles and  $10^{11}$  viral particles for a patient with antibody negative to the virus, while it is set about  $10^7$  viral particles or less for a patient with antibody positive to the virus.

13. (Original) The cancer gene therapeutic method according to claim 10, wherein one administration rate of the oncolytic virus through the carrier cell is set between about  $10^9$  viral particles and  $10^{14}$  viral particles.

14. (Original) The cancer gene therapeutic method according to claim 10, wherein the amount of infection of the oncolytic virus to the carrier cell is set between about 0.1 viral particles/cell and 2,000 viral particles/cell.

15. (Currently amended) The cancer gene therapeutic method according to claim 10, further comprising administrating the carrier cell by intratumor injection.

16. (Currently amended) The cancer gene therapeutic method according to claim 10, further comprising administrating atelocollagen together with the carrier cell.

17. (Currently amended) The cancer gene therapeutic method according to claim 10, further comprising administrating the carrier cell infected with ~~not only the oncolytic virus and but also~~ a GM-CSF expression vector.

18. (Currently amended) The cancer gene therapeutic method according to claim 10, further comprising administrating an iron preparation and/or a porphyrin compound, together with the carrier cell.

19. (Currently amended) The cancer gene therapeutic method according to claim 10, further comprising administrating a tumor cell for tumor vaccination, together with, before or after administration of the virus for immunological treatment.

20. (New) The cancer gene therapeutic drug according to claim 2, wherein the virus for immunological treatment is a non-proliferative type and/or an inactivated virus.

21. (New) The cancer gene therapeutic drug according to claim 2, wherein the carrier cell is selected from the group consisting of A549 cell, 293 cell, SW626 cell, HT-3 cell, PA-1 cell, a human derived cancer cell, and a human normal cell.

22. (New) The cancer gene therapeutic drug according to claim 3, wherein the carrier cell is selected from the group consisting of A549 cell, 293 cell, SW626 cell, HT-3 cell, PA-1 cell, a human derived cancer cell, and a human normal cell.

23. (New) The cancer gene therapeutic drug according to claim 20, wherein the carrier cell is selected from the group consisting of A549 cell, 293 cell, SW626 cell, HT-3 cell, PA-1 cell, a human derived cancer cell, and a human normal cell.